Further validation via dysadherin knockdown (KD) using the most effective siRNA sequence (#3) confirmed CA9 downregulation in SNU-254 cells (rectal cancer) and patient-derived primary cells (Table S3) (Supplementary Fig. 4i–k). Here, FXYD5 is linked to rectal cancer.